logo-loader
viewTonix Pharmaceuticals

Full interview: Tonix Pharmaceuticals doses first patient in Phase 1 trial to treat PTSD

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) President and CEO Seth Lederman tells Proactive the New York-based biopharma has begun dosing patients suffering from post-traumatic stress disorder in a Phase 1 study with its daytime therapy TNX-601.

Lederman says TNX-601 is one of three drug candidates the company is developing for PTSD, with its most advanced being TNX-102 SL, currently in Phase 3 development.

Quick facts: Tonix Pharmaceuticals

Price: 1.64 USD

NASDAQ:TNXP
Market: NASDAQ
Market Cap: $13.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tonix Pharmaceuticals named herein, including the promotion by the Company of Tonix Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tonix Pharmaceuticals reveals exciting upcoming milestones in its Phase 3...

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Seth Lederman sat down with Proactive at the Biotech Showcase 2020 in San Francisco. Lederman talks about expected interim analysis of its Phase 3 trial in PTSD and expected topline data results. He adds its Phase 3 study in fibromyalgia is...

1 week, 6 days ago

2 min read